Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I gathered all the data I have and I came to the conclusion that they announce the success of the phase 3 in ovarian cancer this coming September
Yes but here we have data that vb111 is doing great 69% response rate in the first 60 patients when fever and at least 58% when non fever is almost too good to be true
$VBLT the word unanimously is missing in this dsmc decision . In previous reports VBL said the decision was made unanimously. It means this time they voted and the majority won minority . There is more chance the minority voted to stop trial due to success than the option they voted to stop trial due to failure. The reason there is more chance is actually 2 reasons. 1. The decision itself by majority to continue means vb-111 isn't failing. 2. The fact the first 60 patients had 10% or more advantage and the fact 55% response rate continued in 200 patients. My conclusion therefore- there were votes in the dsmc that thought the trial should be stopped due to success
Trial ends 1q 2021 and top line data 1q 2021
In recent presentation at Wainwright convention CEO said they can lead to 70% of patients to react with fever but they reach only 40% by killing the fever using corticosteroids and other fever killer drugs. This company keep making crucial mistakes that destroy their effective anti cancer drug. Right before he mentioned this fact he said we have 70% response rate in patients that react with fever. Moreover ,if you look at the data of the failed GLOBE phase 3 trial in gbm you will notice that febrile patients lived longer than control arm. If the people from VBL could induce fever in 70% of patients in GLOBE TRIAL we may have had a successful trial also in GBM
Rumour in stocktwits saying there is a merger being announced soon
I dont recommend to buy but it's definitely a hold. The drug works and surprises here can happen. I hold strong
1 more year to buy the stock at price of $1 ? I still gamble on their success and keep buying . All the past users here and in other forum left this loser stock but I believe in long term investments especially in biotech. It can take 20 years before you make money out of these companies. Thank God i have patience of even 100 years in stock market. I plan to make a fortune from this company. I predict huge success here in the ovarian cancer phase 3 trial. 2021 is the year to become rich here
It's old news just presentation . The good news hopefully q3 in second interim. Good luck
I m.holding
They mentioned 69% responders in febrile patients so it's obvious most of the complete responders if not all of them are in treatment arm.
The CEO already spoke today about next interim in OVAL That is suppose to take place in February 2021. This is important because he wouldn't speak about this far interim without knowing the coming interim in august this year is sucessfull
They hid 9 complete responders. It was revealed in the conference call 2 PM few hours after PR. Anybody has an idea why to hide ? I have never seen anything like that before
. "So I can tell you that the percentage of patients developing fever is actually similar to what we've seen in all our Phase 2 trials, is about 40% so far. I can tell you that in the blinded data, the one developing fever, doing quite well in their C-125 response. So there are a lot of signals that we have a good chance to repeat what we've seen in the Phase 2"
Am I get it right ? Did they ceo just said we know that in the phase 3 40% reacted with fever and we also know these 40% had reduction in ca125 ? If yes then he just revealed a readout of 80% of interim because he said 20% missing from 60 patients before that
I do not know. I know it will be published before March 2020 and I hope for hood results. Past events I try to ignore.
According to an Israeli interview Dror Haraz the CEO said something I never heard from him before and I m asking u if u believe him. So far there was only one time he said something and it didn't happen that I can remember and it was the lung cancer trial but I think the reason was change of mind of the Japanese company . Dror Haraz said in the interview as follow. UCLA scientist analysed results of a trial we thought that totally failed and found it was not a real failure but confirmation of our technology
Since these scientist work as advisors to the FDA some big companies are back to sit with us on the table to talk about purchasing us. He said that if we compare it to mating there is the first act then the dance and then the intimic dance we are now at the intimic dance stage and he finished by saying I hope I can come to the public with an announcement soon . I wouldn't run to buy the stock due to me being sceptical but I would love to hear your thoughts
Check in google nano carrier latest presentation
HARVARD UNIVERSITY AFFILIATE HOSPITAL
Nano carrier confirmed hardware affiliates hospital will do and pay for new rgbm ph2 trial
I was happy to hear they plan to try vb-111 without avastin in GBM and more but I was very disappointed to hear they allow avastin after progression in gbm. I believe it's a huge mistake to add avastin at anytime. Sometimes doctors think it's a progression and it's not and also avastin destroy the immune response. Brain implant won't hurt these guys at VBL as if they didn't each enough shit from the devil avastin
Next step is ovarian . They must succeed. Fever is the key. Unfortunately they don't push to fever like injecting directly to tumor and they still reduce fever using anti fever drugs. The only hope is the good ph2 result in ovarian
Among patients in the combination arm, OS was 7.9 vs 5.5 in patients with and without a febrile reaction.
Yes. Let's see if they publish what happened after the trial closed. The more interesting info is coming beginning next year 2 patients from the ovarian phase 3 biopsy will be published 2 out of 2 in treatment arm.
From what it looks like the vb111 arm did worse than the ph2 and even worse than avastin alone. From what's on the surface I think they are going to concentrate in ovarian ph3 only and try maybe ph2 on other cancer.
Need to watch Tocagen phase 3 results. If they show great success I believe it's due to virus being injected directly to the tumor . If toca shows success the fact vblt virus was given systemically can be the main reason of failure.
They said the reconsider the whole program of vb111. You will hear new plans and regiments soon. They said that more than once so expect it to happen soon. They said summer which means August.
They will publish it . It won't send the stock down. I believe fever will be key in results and it will show again how clueless useless and kaput they are and the fda. After all the fda will never agree to add fever as an inclusion criteria but let's see first the results.
They should all resign. They are useless. Zero creativity thinking and they care less about vb111 success just milking options
The fact trial last so long. The fact CEO said he will ask fda to change protocol in ovarian for doctor and patients to be blinded to the drug they receive plus him saying the results are very different than the phase 2 . It leaves as with avastin group doing very well and live even longer than 11 months median.
All the signs u.ply avastin group only did very well probably lived over even 11 months in the median. The official excuse will be dropouts...
The CEO was proud about how convenient it's that it's only once in 8 weeks and an easy IV . In the war against cancer especially the ones that kill fast ovarian included you must be aggressive and attack also tumor directly with the virus. It's convenient also to treat fever... the cancer celebrated on their drug. They must have major changes not only minor changes in ovarian
Any aggressive use with vb111 will show better results
If the wrong doing continues expect horrible outcomes. The wrong doing was mentioned many times before the fiasco in gbm. How could it be that me and my trash can have to teach these dedicated experts with all kind of degree how to do the things right is beyond me.
1 treating the fever - wrong
2. Combination with the devil avastin - wrong
3. Not injecting vb111 directly to tumor - wrong
The adjustments were to cancel interim futility and the second one was to extend the trial to 189 death instead of around 155 death it was planned to be stopped. The answer to your second question is yes any day that pass beyond data cutoff changes the data
They should add another arm to vb111. Not gene therapy but viral oncology even if the price is a new phase 2. They need to add another arm of injecting the virus directly to the tumor in addition to systemic delivery. If they do that the market will understand the changes
But I agree that next substantial climb will be only in 4 or 5 years from now if success
Instead of you I will wait with short to the day they announce the failure details . Maybe a pop there if there will be will be safer short or not. Anyway look at results details to decide
Fda probably insisted on it to be as it was designed